A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of JL18008 Injection in HIV-Infected Immunological Non-Responders
Latest Information Update: 05 Mar 2026
At a glance
- Drugs JL 18008 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors JECHO Biopharmaceuticals
Most Recent Events
- 05 Mar 2026 New trial record